secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001104659-22-114413
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 2.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q3 2022 net loss $19.0M, TAVALISSE sales up 20%, workforce cut 16%
------------------------------------------------------------------------

- Q3 net loss $19.0M ($0.11/sh) vs $21.0M loss a year ago; total revenue $22.4M.
- TAVALISSE net product sales $19.2M, up 20% YoY from $16.0M.
- Reduced workforce by 16% (30 positions) in development and administration.
- Olutasidenib NDA under FDA review with PDUFA date Feb 15, 2023; preparations for launch.
- FOCUS COVID-19 Phase 3 trial missed primary endpoint (p=0.0603); no sNDA for wAIHA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922114413/0001104659-22-114413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922114413/tm2229578d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-114413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer